RQ Bio
Biotech / antibodies, London
Develops long-acting antibody RQB01 for full-season influenza prevention. It raised £85.5m in its Series A in June 2026. We can't read its job board yet.
Backed by EQT Life Sciences, Forbion, Frazier Life Sciences and LifeArc Ventures.
On the Home Office register of licensed visa sponsors.
Open roles over time
We can't read this company's job board yet.
Hiring momentum
Roles per weekNot tracked yet.
In the news
- LeadershipThe Pharma Letter, 27 days agoRQ Bio announces exec appointments
- OtherBioPharma Dive, 24 Jun 2026Investors pour $115M into RQ Bio in search of a preventive flu drug
- OtherFierce Biotech, 24 Jun 2026RQ Bio reels in $115M to take long-acting flu prevention antiviral into clinic
- OtherFirstWord, 24 Jun 2026With $115M in hand, RQ Bio takes aim at flu preventative
- FundingGlobeNewswire, 24 Jun 2026RQ Bio Announces $115 Million (£85.5 Million) Series A